Characterization of carfilzomib-resistant non-small cell lung cancer cell lines View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-05-15

AUTHORS

Neale T. Hanke, Elliot Imler, Marilyn T. Marron, Bruce E. Seligmann, Linda L. Garland, Amanda F. Baker

ABSTRACT

PurposeWe previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines. Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines.MethodsCFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concentrations of CFZ. Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay. Cytotoxicity to CFZ was determined using a CytoTox assay. Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins. Quantitative targeted whole transcriptome sequencing and quantitative RT-PCR was used to measure gene expression. Flow cytometry was used to analyze intracellular accumulation of doxorubicin.ResultsThe CFZ IC50 value of the resistant cells increased versus parental lines (2.5-fold for A549, 122-fold for H520). Resistant lines showed reduced expression of apoptosis and autophagy markers and reduced death versus parental lines following CFZ treatment. Both resistant lines exhibited higher P-glycoprotein (Pgp) gene (TempO-Seq® analysis, increased 1.2-fold in A549, > 9000-fold in H520) and protein expression levels versus parental lines. TempO-Seq® analysis indicated other drug resistance pathways were upregulated. The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin.ConclusionsUpregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines. More... »

PAGES

1317-1327

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-018-2662-0

DOI

http://dx.doi.org/10.1007/s00432-018-2662-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103994980

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29766327


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "A549 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily B, Member 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Death", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanke", 
        "givenName": "Neale T.", 
        "id": "sg:person.01231024471.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231024471.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BioSpyder Technologies Inc, Carlsbad, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.465144.6", 
          "name": [
            "BioSpyder Technologies Inc, Carlsbad, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imler", 
        "givenName": "Elliot", 
        "id": "sg:person.01323346006.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323346006.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BioSpyder Technologies Inc, Carlsbad, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.465144.6", 
          "name": [
            "BioSpyder Technologies Inc, Carlsbad, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marron", 
        "givenName": "Marilyn T.", 
        "id": "sg:person.01343121163.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343121163.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BioSpyder Technologies Inc, Carlsbad, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.465144.6", 
          "name": [
            "BioSpyder Technologies Inc, Carlsbad, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seligmann", 
        "givenName": "Bruce E.", 
        "id": "sg:person.01014063606.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014063606.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garland", 
        "givenName": "Linda L.", 
        "id": "sg:person.01322145005.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ventana Medical Systems, Inc., A Member of the Roche Group, 1910 East Innovation Park Drive, 85755, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA", 
            "Ventana Medical Systems, Inc., A Member of the Roche Group, 1910 East Innovation Park Drive, 85755, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baker", 
        "givenName": "Amanda F.", 
        "id": "sg:person.01067534552.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067534552.92"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-3-319-06752-0_5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040589924", 
          "https://doi.org/10.1007/978-3-319-06752-0_5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2267-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034718690", 
          "https://doi.org/10.1007/s00280-013-2267-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1476-4598-9-110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010792359", 
          "https://doi.org/10.1186/1476-4598-9-110"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-015-2047-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052308469", 
          "https://doi.org/10.1007/s00432-015-2047-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bcj.2017.56", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090307601", 
          "https://doi.org/10.1038/bcj.2017.56"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021356437", 
          "https://doi.org/10.1038/leu.2009.8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13046-014-0111-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015832532", 
          "https://doi.org/10.1186/s13046-014-0111-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1210028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008625838", 
          "https://doi.org/10.1038/sj.onc.1210028"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2015.289", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040701560", 
          "https://doi.org/10.1038/leu.2015.289"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13059-014-0550-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015222646", 
          "https://doi.org/10.1186/s13059-014-0550-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-05-15", 
    "datePublishedReg": "2018-05-15", 
    "description": "PurposeWe previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines. Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines.MethodsCFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concentrations of CFZ. Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay. Cytotoxicity to CFZ was determined using a CytoTox assay. Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins. Quantitative targeted whole transcriptome sequencing and quantitative RT-PCR was used to measure gene expression. Flow cytometry was used to analyze intracellular accumulation of doxorubicin.ResultsThe CFZ IC50 value of the resistant cells increased versus parental lines (2.5-fold for A549, 122-fold for H520). Resistant lines showed reduced expression of apoptosis and autophagy markers and reduced death versus parental lines following CFZ treatment. Both resistant lines exhibited higher P-glycoprotein (Pgp) gene (TempO-Seq\u00ae analysis, increased 1.2-fold in A549, >\u20099000-fold in H520) and protein expression levels versus parental lines. TempO-Seq\u00ae analysis indicated other drug resistance pathways were upregulated. The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin.ConclusionsUpregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-018-2662-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438836", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "144"
      }
    ], 
    "keywords": [
      "lung cancer cell lines", 
      "non-small cell lung cancer cell lines", 
      "cell lung cancer cell lines", 
      "cancer cell lines", 
      "cell lines", 
      "NSCLC cell lines", 
      "resistant cell lines", 
      "protein expression levels", 
      "CFZ treatment", 
      "CFZ resistance", 
      "quantitative RT-PCR", 
      "drug resistance pathways", 
      "H520 cells", 
      "carfilzomib", 
      "intracellular doxorubicin", 
      "chemotherapy drugs", 
      "flow cytometry", 
      "Western blot", 
      "autophagy markers", 
      "resistant cells", 
      "reduced expression", 
      "RT-PCR", 
      "intracellular accumulation", 
      "MTT assay", 
      "whole transcriptome sequencing", 
      "expression levels", 
      "parental lines", 
      "doxorubicin", 
      "cytotoxic activity", 
      "drugs", 
      "IC50 values", 
      "resistance pathways", 
      "resistant lines", 
      "possible mechanism", 
      "apoptosis", 
      "glycoprotein gene", 
      "gene expression", 
      "assays", 
      "cells", 
      "TempO-Seq", 
      "bortezomib", 
      "less accumulation", 
      "expression", 
      "PurposeWe", 
      "transcriptome sequencing", 
      "ConclusionsUpregulation", 
      "paclitaxel", 
      "cisplatin", 
      "cytometry", 
      "death", 
      "blot", 
      "treatment", 
      "Pgp", 
      "resistance", 
      "A549", 
      "markers", 
      "cytotoxicity", 
      "accumulation", 
      "autophagy", 
      "lines", 
      "mechanism", 
      "pathway", 
      "levels", 
      "activity", 
      "protein", 
      "sequencing", 
      "genes", 
      "broad range", 
      "quantitative", 
      "concentration", 
      "analysis", 
      "values", 
      "characterization", 
      "range"
    ], 
    "name": "Characterization of carfilzomib-resistant non-small cell lung cancer cell lines", 
    "pagination": "1317-1327", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103994980"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-018-2662-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29766327"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-018-2662-0", 
      "https://app.dimensions.ai/details/publication/pub.1103994980"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_757.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-018-2662-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2662-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2662-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2662-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2662-0'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      22 PREDICATES      121 URIs      103 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-018-2662-0 schema:about N0235c479869742e08027da250d17eb2d
2 N257ddc85180246389997194ce87f8356
3 N281433eace4140248d2c3b7f13624151
4 N2e3d8db570104a33880535df17642097
5 N5a26aff1050b45e18451e518c14cfdb0
6 N9f2484bb8b2949f9a1b1caac37be162f
7 Na254781c63a540c1aed30dee67311843
8 Na621b52e72d74c9bbeb82f833c9d16f2
9 Ncbe2dd56c62d4db9a091651ec3bb096e
10 Ndeabb4c577b04583ae6bf869c43d9f91
11 Nf4c7e873b79342a1821073753a3154e8
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author N958d01a3c94844d89f868123f0603a00
15 schema:citation sg:pub.10.1007/978-3-319-06752-0_5
16 sg:pub.10.1007/s00280-013-2267-x
17 sg:pub.10.1007/s00432-015-2047-6
18 sg:pub.10.1038/bcj.2017.56
19 sg:pub.10.1038/leu.2009.8
20 sg:pub.10.1038/leu.2015.289
21 sg:pub.10.1038/sj.onc.1210028
22 sg:pub.10.1186/1476-4598-9-110
23 sg:pub.10.1186/s13046-014-0111-8
24 sg:pub.10.1186/s13059-014-0550-8
25 schema:datePublished 2018-05-15
26 schema:datePublishedReg 2018-05-15
27 schema:description PurposeWe previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines. Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines.MethodsCFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concentrations of CFZ. Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay. Cytotoxicity to CFZ was determined using a CytoTox assay. Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins. Quantitative targeted whole transcriptome sequencing and quantitative RT-PCR was used to measure gene expression. Flow cytometry was used to analyze intracellular accumulation of doxorubicin.ResultsThe CFZ IC50 value of the resistant cells increased versus parental lines (2.5-fold for A549, 122-fold for H520). Resistant lines showed reduced expression of apoptosis and autophagy markers and reduced death versus parental lines following CFZ treatment. Both resistant lines exhibited higher P-glycoprotein (Pgp) gene (TempO-Seq® analysis, increased 1.2-fold in A549, > 9000-fold in H520) and protein expression levels versus parental lines. TempO-Seq® analysis indicated other drug resistance pathways were upregulated. The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin.ConclusionsUpregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N0dafdddab76642e5a40c30477223d308
32 N602c3662d8bf48c2b83777850c90b71b
33 sg:journal.1313647
34 schema:keywords A549
35 CFZ resistance
36 CFZ treatment
37 ConclusionsUpregulation
38 H520 cells
39 IC50 values
40 MTT assay
41 NSCLC cell lines
42 Pgp
43 PurposeWe
44 RT-PCR
45 TempO-Seq
46 Western blot
47 accumulation
48 activity
49 analysis
50 apoptosis
51 assays
52 autophagy
53 autophagy markers
54 blot
55 bortezomib
56 broad range
57 cancer cell lines
58 carfilzomib
59 cell lines
60 cell lung cancer cell lines
61 cells
62 characterization
63 chemotherapy drugs
64 cisplatin
65 concentration
66 cytometry
67 cytotoxic activity
68 cytotoxicity
69 death
70 doxorubicin
71 drug resistance pathways
72 drugs
73 expression
74 expression levels
75 flow cytometry
76 gene expression
77 genes
78 glycoprotein gene
79 intracellular accumulation
80 intracellular doxorubicin
81 less accumulation
82 levels
83 lines
84 lung cancer cell lines
85 markers
86 mechanism
87 non-small cell lung cancer cell lines
88 paclitaxel
89 parental lines
90 pathway
91 possible mechanism
92 protein
93 protein expression levels
94 quantitative
95 quantitative RT-PCR
96 range
97 reduced expression
98 resistance
99 resistance pathways
100 resistant cell lines
101 resistant cells
102 resistant lines
103 sequencing
104 transcriptome sequencing
105 treatment
106 values
107 whole transcriptome sequencing
108 schema:name Characterization of carfilzomib-resistant non-small cell lung cancer cell lines
109 schema:pagination 1317-1327
110 schema:productId N120c4baaaec8400087137dbe02219093
111 N6615c950db2247e5a8b6610c55429c78
112 Nee8158195fd242d8b6d2976d341b0b6f
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103994980
114 https://doi.org/10.1007/s00432-018-2662-0
115 schema:sdDatePublished 2022-05-20T07:34
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher N06544e7191c34b8d84e78ed47ce6bfb7
118 schema:url https://doi.org/10.1007/s00432-018-2662-0
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N0235c479869742e08027da250d17eb2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Drug Resistance, Neoplasm
124 rdf:type schema:DefinedTerm
125 N0487ef3c215f4a1fb58c56b5c30a8a59 rdf:first sg:person.01343121163.54
126 rdf:rest Ncf875e90386f4e6394656192368aacbf
127 N06544e7191c34b8d84e78ed47ce6bfb7 schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 N0d79124d3f574cba908a76106c615119 rdf:first sg:person.01067534552.92
130 rdf:rest rdf:nil
131 N0dafdddab76642e5a40c30477223d308 schema:volumeNumber 144
132 rdf:type schema:PublicationVolume
133 N120c4baaaec8400087137dbe02219093 schema:name pubmed_id
134 schema:value 29766327
135 rdf:type schema:PropertyValue
136 N24424153f2e74508a76178b5069a3281 rdf:first sg:person.01322145005.35
137 rdf:rest N0d79124d3f574cba908a76106c615119
138 N257ddc85180246389997194ce87f8356 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cell Death
140 rdf:type schema:DefinedTerm
141 N281433eace4140248d2c3b7f13624151 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Lung Neoplasms
143 rdf:type schema:DefinedTerm
144 N2e3d8db570104a33880535df17642097 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Oligopeptides
146 rdf:type schema:DefinedTerm
147 N5a26aff1050b45e18451e518c14cfdb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N602c3662d8bf48c2b83777850c90b71b schema:issueNumber 7
151 rdf:type schema:PublicationIssue
152 N6615c950db2247e5a8b6610c55429c78 schema:name doi
153 schema:value 10.1007/s00432-018-2662-0
154 rdf:type schema:PropertyValue
155 N958d01a3c94844d89f868123f0603a00 rdf:first sg:person.01231024471.66
156 rdf:rest Nade0a3f350fc4945b30fa857ce83be7d
157 N9f2484bb8b2949f9a1b1caac37be162f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Carcinoma, Non-Small-Cell Lung
159 rdf:type schema:DefinedTerm
160 Na254781c63a540c1aed30dee67311843 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name A549 Cells
162 rdf:type schema:DefinedTerm
163 Na621b52e72d74c9bbeb82f833c9d16f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Cell Proliferation
165 rdf:type schema:DefinedTerm
166 Nade0a3f350fc4945b30fa857ce83be7d rdf:first sg:person.01323346006.87
167 rdf:rest N0487ef3c215f4a1fb58c56b5c30a8a59
168 Ncbe2dd56c62d4db9a091651ec3bb096e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Cell Line, Tumor
170 rdf:type schema:DefinedTerm
171 Ncf875e90386f4e6394656192368aacbf rdf:first sg:person.01014063606.33
172 rdf:rest N24424153f2e74508a76178b5069a3281
173 Ndeabb4c577b04583ae6bf869c43d9f91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Antineoplastic Agents
175 rdf:type schema:DefinedTerm
176 Nee8158195fd242d8b6d2976d341b0b6f schema:name dimensions_id
177 schema:value pub.1103994980
178 rdf:type schema:PropertyValue
179 Nf4c7e873b79342a1821073753a3154e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name ATP Binding Cassette Transporter, Subfamily B, Member 1
181 rdf:type schema:DefinedTerm
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
186 schema:name Oncology and Carcinogenesis
187 rdf:type schema:DefinedTerm
188 sg:grant.2438836 http://pending.schema.org/fundedItem sg:pub.10.1007/s00432-018-2662-0
189 rdf:type schema:MonetaryGrant
190 sg:journal.1313647 schema:issn 0171-5216
191 1432-1335
192 schema:name Journal of Cancer Research and Clinical Oncology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01014063606.33 schema:affiliation grid-institutes:grid.465144.6
196 schema:familyName Seligmann
197 schema:givenName Bruce E.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014063606.33
199 rdf:type schema:Person
200 sg:person.01067534552.92 schema:affiliation grid-institutes:grid.418158.1
201 schema:familyName Baker
202 schema:givenName Amanda F.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067534552.92
204 rdf:type schema:Person
205 sg:person.01231024471.66 schema:affiliation grid-institutes:grid.134563.6
206 schema:familyName Hanke
207 schema:givenName Neale T.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231024471.66
209 rdf:type schema:Person
210 sg:person.01322145005.35 schema:affiliation grid-institutes:grid.134563.6
211 schema:familyName Garland
212 schema:givenName Linda L.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35
214 rdf:type schema:Person
215 sg:person.01323346006.87 schema:affiliation grid-institutes:grid.465144.6
216 schema:familyName Imler
217 schema:givenName Elliot
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323346006.87
219 rdf:type schema:Person
220 sg:person.01343121163.54 schema:affiliation grid-institutes:grid.465144.6
221 schema:familyName Marron
222 schema:givenName Marilyn T.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343121163.54
224 rdf:type schema:Person
225 sg:pub.10.1007/978-3-319-06752-0_5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040589924
226 https://doi.org/10.1007/978-3-319-06752-0_5
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/s00280-013-2267-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034718690
229 https://doi.org/10.1007/s00280-013-2267-x
230 rdf:type schema:CreativeWork
231 sg:pub.10.1007/s00432-015-2047-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052308469
232 https://doi.org/10.1007/s00432-015-2047-6
233 rdf:type schema:CreativeWork
234 sg:pub.10.1038/bcj.2017.56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090307601
235 https://doi.org/10.1038/bcj.2017.56
236 rdf:type schema:CreativeWork
237 sg:pub.10.1038/leu.2009.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021356437
238 https://doi.org/10.1038/leu.2009.8
239 rdf:type schema:CreativeWork
240 sg:pub.10.1038/leu.2015.289 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040701560
241 https://doi.org/10.1038/leu.2015.289
242 rdf:type schema:CreativeWork
243 sg:pub.10.1038/sj.onc.1210028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008625838
244 https://doi.org/10.1038/sj.onc.1210028
245 rdf:type schema:CreativeWork
246 sg:pub.10.1186/1476-4598-9-110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010792359
247 https://doi.org/10.1186/1476-4598-9-110
248 rdf:type schema:CreativeWork
249 sg:pub.10.1186/s13046-014-0111-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015832532
250 https://doi.org/10.1186/s13046-014-0111-8
251 rdf:type schema:CreativeWork
252 sg:pub.10.1186/s13059-014-0550-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015222646
253 https://doi.org/10.1186/s13059-014-0550-8
254 rdf:type schema:CreativeWork
255 grid-institutes:grid.134563.6 schema:alternateName College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
256 schema:name College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
257 rdf:type schema:Organization
258 grid-institutes:grid.418158.1 schema:alternateName Ventana Medical Systems, Inc., A Member of the Roche Group, 1910 East Innovation Park Drive, 85755, Tucson, AZ, USA
259 schema:name College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
260 Ventana Medical Systems, Inc., A Member of the Roche Group, 1910 East Innovation Park Drive, 85755, Tucson, AZ, USA
261 rdf:type schema:Organization
262 grid-institutes:grid.465144.6 schema:alternateName BioSpyder Technologies Inc, Carlsbad, CA, USA
263 schema:name BioSpyder Technologies Inc, Carlsbad, CA, USA
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...